117 related articles for article (PubMed ID: 2366866)
1. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene.
Erickson LA; Fici GJ; Lund JE; Boyle TP; Polites HG; Marotti KR
Nature; 1990 Jul; 346(6279):74-6. PubMed ID: 2366866
[TBL] [Abstract][Full Text] [Related]
2. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis.
Sartori MT; Wiman B; Vettore S; Dazzi F; Girolami A; Patrassi GM
Thromb Haemost; 1998 Dec; 80(6):956-60. PubMed ID: 9869167
[TBL] [Abstract][Full Text] [Related]
3. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
4. A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency.
Zöller B; García de Frutos P; Dahlbäck B
Thromb Haemost; 1998 Apr; 79(4):802-7. PubMed ID: 9569196
[TBL] [Abstract][Full Text] [Related]
5. Impaired fibrinolysis in obstructive jaundice--evidence from clinical and experimental studies.
Colucci M; Altomare DF; Chetta G; Triggiani R; Cavallo LG; Semeraro N
Thromb Haemost; 1988 Aug; 60(1):25-9. PubMed ID: 3142090
[TBL] [Abstract][Full Text] [Related]
6. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.
Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F
Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812
[TBL] [Abstract][Full Text] [Related]
7. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism.
Stegnar M; Uhrin P; Peternel P; Mavri A; Salobir-Pajnic B; Stare J; Binder BR
Thromb Haemost; 1998 May; 79(5):975-9. PubMed ID: 9609232
[TBL] [Abstract][Full Text] [Related]
8. Clot lysis: role of plasminogen activator inhibitors in haemostasis and therapy.
Pawse AR; Tarachand U
Indian J Exp Biol; 1997 Jun; 35(6):545-52. PubMed ID: 9357156
[TBL] [Abstract][Full Text] [Related]
9. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator.
Deng A; Gocke CD; Hess J; Heyman M; Paltiel M; Gaspari A
Arch Dermatol; 2006 Nov; 142(11):1466-9. PubMed ID: 17116837
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
Petersen KR
Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
[TBL] [Abstract][Full Text] [Related]
11. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
13. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
14. The role of fibrinolytic factors in ischaemia.
Pandolfi M; al-Rushood A
Eye (Lond); 1991; 5 ( Pt 2)():159-69. PubMed ID: 2070877
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice.
Zhou HM; Bolon I; Nichols A; Wohlwend A; Vassalli JD
Cancer Res; 2001 Feb; 61(3):970-6. PubMed ID: 11221892
[TBL] [Abstract][Full Text] [Related]
16. Elevated plasminogen activator inhibitor (PAI), a cause of thrombophilia? A study in 203 patients with familial or sporadic venous thrombophilia.
Engesser L; Brommer EJ; Kluft C; Briët E
Thromb Haemost; 1989 Sep; 62(2):673-80. PubMed ID: 2683188
[TBL] [Abstract][Full Text] [Related]
17. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury.
Idell S
Crit Care Med; 2003 Apr; 31(4 Suppl):S213-20. PubMed ID: 12682443
[TBL] [Abstract][Full Text] [Related]
18. Familial association of high levels of histidine-rich glycoprotein and plasminogen activator inhibitor-1 with venous thromboembolism.
Angles-Cano E; Gris JC; Loyau S; Schved JF
J Lab Clin Med; 1993 May; 121(5):646-53. PubMed ID: 8478593
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
Allan EH; Martin TJ
J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of endogenous fibrinolysis does not reduce local fibrin deposition, but modulates inflammation upon intestinal ischemia and reperfusion.
Schoots IG; Levi M; van Vliet AK; Declerck PJ; Maas AM; van Gulik TM
Thromb Haemost; 2004 Mar; 91(3):497-505. PubMed ID: 14983225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
